Stay updated on Nivolumab in CNS and Testicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in CNS and Testicular Lymphoma Clinical Trial page.

Latest updates to the Nivolumab in CNS and Testicular Lymphoma Clinical Trial page
- ChecktodayChange DetectedThe study record no longer lists the NIH grant/contract identifier “2016,” and the site revision advances from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoChange DetectedThe study record and its displayed details appear unchanged.SummaryDifference0.0%

- Check14 days agoChange DetectedThe ClinicalTrials.gov record for the nivolumab study in relapsed or refractory PCNSL and PTL is available, with study details, results measures, eligibility requirements, and participating locations.SummaryDifference70%

- Check21 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0 on the 403 error page.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide notice says NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to transition updates. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Nivolumab in CNS and Testicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in CNS and Testicular Lymphoma Clinical Trial page.